3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Phase 1/2
1
Status
Unknown
1
Terminated
1
Completed
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
3
Observational
1
Sponsor
Cancer Type
Gastrointestinal
3
Conditions
Carcinoma, Non-Small-Cell Lung
31
Carcinoma, Hepatocellular
18
Neoplasms
13
Neoplasm Metastasis
13
Melanoma
13
Esophageal Neoplasms
12
Nasopharyngeal Carcinoma
10
Head and Neck Neoplasms
9
Esophageal Squamous Cell Carcinoma
9
Colorectal Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
8
Breast Neoplasms
8
Triple Negative Breast Neoplasms
7
Stomach Neoplasms
7
Recurrence
7
Pancreatic Neoplasms
7
Rectal Neoplasms
6
Carcinoma, Renal Cell
6
Biliary Tract Neoplasms
6
Lung Neoplasms
5
Small Cell Lung Carcinoma
4
Sarcoma
4
Ovarian Neoplasms
4
Locally Advanced Rectal Cancer
4
Colonic Neoplasms
4
Advanced NSCLC
4
Urinary Bladder Neoplasms
3
Prostatic Neoplasms
3
Liver Neoplasms
3
Leukemia, Myeloid, Acute
3
Interventions
Sorafenib
61
Bevacizumab
42
Oxaliplatin
24
Doxorubicin
22
Radiosurgery
20
Gemcitabine
20
Fluorouracil
20
Nivolumab
19
durvalumab
18
Radiofrequency Ablation
18
pembrolizumab
17
Capecitabine
17
lenvatinib
16
Cisplatin
16
atezolizumab
13
Leucovorin
13
Radiotherapy
11
tremelimumab
10
Cyclophosphamide
10
Carboplatin
10
Irinotecan
9
Ipilimumab
9
Drug Therapy
9
Everolimus
8
Cryosurgery
8
toripalimab
7
fludarabine
7
Sunitinib
7
Chemotherapy, Adjuvant
7
Melphalan
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Interventional
×
Liver Neoplasms
×
Immune Checkpoint Inhibitors
×
Clear all
NCT05497453
2025-02-03
MYCHELANGELO I
Omega Therapeutics
Phase 1/2
Terminated
24 enrolled
NCT03817736
2024-05-09
START-FIT
The University of Hong Kong
Phase 2
Completed
33 enrolled
NCT05322187
2022-04-11
sPLENTY-pc
RenJi Hospital
Phase 2/3
Unknown
15 enrolled